AI-assisted nano antibody recombinant expression production management system and application
Through the AI-assisted nano-antibody recombinant expression production management system, the problems of low efficiency and insufficient accuracy of recombinant protein expression management in the existing technology are solved, more efficient experimental condition design and process control are achieved, and the production of nano-antibody is improved. Solubility, stability and purity.
Patent Information
- Application Number
- CN202411080329.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-12-03
AI Technical Summary
The existing laboratory management system for recombinant protein expression is inefficient and the accuracy is not stable enough, and it mainly relies on artificial experience and experimental observation, resulting in low management efficiency and insufficient accuracy.
Using AI-assisted nano-antibody recombinant expression production management system, including experimental condition design module, process management module and production effect processing module, the training model recommends optimization of experimental conditions, manages experimental steps sequence, evaluates and optimizes yield, solubility, stability and Purity data, generate abnormal coefficients for feedback and optimization.
It improves the management efficiency of nano-antibody recombinant expression, avoids the limitations of artificial experience, realizes more efficient experimental condition design and process control, and improves yield, solubility, stability and purity.
Smart Images

Figure CN119068984A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to an AI-assisted production management system for nano-antibody recombinant expression and its application. Background Art
[0002] The laboratory management system for recombinant protein expression needs to manage the following three parts:
[0003] 1. Vector construction: A suitable vector needs to be designed to carry the nanobody gene.
[0004] 2. Protein expression: Use the constructed vector to transform it into the bacterial host through methods such as thermal transformation, and then induce expression through IPTG to trigger the synthesis of nanoantibody protein.
[0005] 3. Protein purification: Once the nanobody protein is successfully expressed in bacteria, it needs to be purified.
[0006] The above management is currently mainly based on human experience and experimental observation, which also have limitations, such as low efficiency and unstable accuracy. Summary of the invention
[0007] In view of this, the embodiments of the present invention provide an AI-assisted production management system and application for nano-antibody recombinant expression to improve management efficiency.
[0008] The embodiment of the present invention discloses an AI-assisted production management system for recombinant expression of nanobodies, comprising:
[0009] The experimental condition design module trains the nanobody recombinant expression and purification model based on the relevant data in the existing nanobody recombinant expression database, recommends more optimized experimental conditions, and predicts the production effect that can be achieved by each combination of experimental conditions;
[0010] Process management module, which sets the order between experimental steps or modules to achieve the management of multiple experiments;
[0011] Production effect processing module, which is used for abnormal evaluation, comparison, early warning and feedback.
[0012] An embodiment of the present invention also discloses the application of an AI-assisted production management system for recombinant expression of nano antibodies. The production management system is applied to vector construction, protein expression and protein purification, evaluates the nano antibody yield, solubility, stability, concentration and purity data, and establishes a data analysis model to generate an abnormality coefficient, and compares the abnormality coefficient with a pre-designed abnormality coefficient reference threshold to complete the recombinant expression of the nano antibody.
[0013] The present invention manages and controls the production process through the design of AI-assisted experimental conditions, evaluates the nanoantibody yield, solubility, stability, concentration and purity data, establishes a data analysis model, avoids human experience and experimental observation, and improves production management efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is a schematic diagram of a production management system according to an embodiment of the present invention.
[0015] Figure 2 This is a schematic diagram of an experimental condition design module according to an embodiment of the present invention.
[0016] Figure 3 It is a schematic diagram of a production effect processing module according to an embodiment of the present invention. DETAILED DESCRIPTION
[0017] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0018] As shown in the figure, the embodiment of the present invention discloses an AI-assisted production management system for recombinant expression of nanobodies, including:
[0019] The experimental condition design module trains the nanobody recombinant expression and purification model based on the relevant data in the existing nanobody recombinant expression database, such as Figure 2 , recommend more optimized experimental conditions and predict the production effect that can be achieved by each combination of experimental conditions;
[0020] Process management module, which sets the order between experimental steps or modules to achieve the management of multiple experiments;
[0021] Production effect processing module, such as Figure 3 ,This module is used for abnormal evaluation, comparison, early warning, and feedback.,The above production management system intervenes in each step of the recombinant expression of nanobodies.
[0022] The present invention discloses an application of an AI-assisted production management system for recombinant expression of nano antibodies. The production management system is applied to vector construction, protein expression and protein purification, evaluates nano antibody yield, solubility, stability, concentration and purity data, establishes a data analysis model, generates an abnormality coefficient, and compares the abnormality coefficient with a pre-designed abnormality coefficient reference threshold. If the abnormality coefficient is greater than the pre-designed abnormality coefficient reference threshold, it means that the experimental conditions designed with AI assistance cannot optimize the experimental conditions to the maximum extent, ultimately leading to problems such as low nano antibody yield, low nano antibody solubility, low nano antibody stability, low concentration and purity, etc.
[0023] In the vector construction step, the experimental condition design module is used to select the vector, restriction enzyme cutting site and antibiotic; in the protein expression step, when the yield, solubility and stability do not meet the standards, one or more of the vector, restriction enzyme cutting site and antibiotic are reselected. For the vector, according to the characteristics of the nanoantibody and the required post-translational modification, a suitable host cell such as Escherichia coli, yeast, insect cells or mammalian cells is selected; for the restriction enzyme cutting site, the size of the DNA fragment generated after the selected enzyme cutting is changed.
[0024] The experimental conditions for vector construction in nanobody recombinant expression mainly include the following aspects:
[0025] Carrier selection:
[0026] It is necessary to select a suitable vector. Common vectors include prokaryotic expression vectors (such as pET series, pGEX series), eukaryotic expression vectors (such as pcDNA series, pIRES series, pCMV series, etc.). Select the corresponding expression vector according to the purpose of the nanoantibody and the host cell type (such as Escherichia coli, yeast, mammalian cells, etc.).
[0027] Nanobody gene cloning:
[0028] The VHH gene of the nanoantibody needs to be obtained through PCR amplification or other methods, and inserted into the appropriate position of the vector through enzyme cutting, ligation, etc. to ensure that the nanoantibody can be correctly paired and expressed.
[0029] Multiple Cloning Site (MCS):
[0030] The vector should have a multiple cloning site composed of multiple restriction enzyme recognition sequences, allowing the nanobody gene fragment to be inserted after specific enzyme cutting, ensuring the correct splicing of the recombinant nanobody VHH gene within the reading frame.
[0031] Promoters and enhancers:
[0032] Strong promoter and enhancer sequences are used to drive the transcriptional expression of nanoantibody genes, ensuring high-level synthesis of nanoantibodies in host cells.
[0033] Translation start and stop signals:
[0034] Appropriate translation initiation signals (such as the Kozak sequence) and stop codons are used to ensure the accurate start and end of Nanobody protein translation.
[0035] Tags and filter tags:
[0036] The vector often carries tags that can assist in protein purification and detection (such as His-tag, GST-tag, etc.), as well as antibiotic resistance genes that facilitate screening of positive clones (such as ampicillin resistance gene, neomycin resistance gene, etc.).
[0037] Splicing signals and signal peptides:
[0038] For eukaryotic expression systems, it may also be necessary to include appropriate splicing signals to facilitate mRNA processing and add signal peptide sequences suitable for the secretory pathway of the target host cell to help the nanoantibody molecules be secreted outside the cell.
[0039] Connection and transformation:
[0040] The ligation reaction requires an appropriate ratio of DNA fragment to vector, working conditions of the ligase and reaction time, after which the ligation product is transformed into the corresponding host cell.
[0041] Clone screening and verification:
[0042] Use culture medium containing selection markers to screen successfully transformed cells, and verify the correct insertion and expression of the nanobody gene in the clone by PCR, enzyme digestion identification, DNA sequencing or nanobody expression detection (such as SDS-PAGE, Western blot, ELISA, etc.).
[0043] Expression optimization:
[0044] Factors such as transfection efficiency, induction conditions, and culture environment may affect the expression level and quality of nanoantibodies, and further optimization is needed to obtain efficiently expressed recombinant nanoantibodies.
[0045] Restriction enzyme cutting site methods and precautions:
[0046] Presence of restriction enzyme cutting sites:
[0047] Analyze the target DNA sequence to be cut to ensure that the recognition sequence of the selected restriction endonuclease exists in the DNA sequence and is located at the appropriate position to facilitate subsequent operations (such as insertion, deletion, replacement, etc.).
[0048] Enzyme digestion efficiency and specificity:
[0049] Select an enzyme with high cleavage efficiency so that it can quickly and completely cut DNA; at the same time, the enzyme should be highly specific to avoid accidental cleavage at non-target sites, thereby reducing nonspecific background.
[0050] Length of digestion product:
[0051] According to the purpose of the experiment, the size of the DNA fragment generated after enzyme digestion is selected to be suitable for the next step (such as electrophoresis resolution, ligation efficiency, vector cloning, etc.).
[0052] Blunt or sticky ends:
[0053] Choose an enzyme that produces blunt ends or sticky ends based on experimental requirements. Sticky ends are conducive to the connection between DNA fragments, while blunt ends require the use of T4 DNA ligase (or homologous recombination and other methods) for connection.
[0054] Multiple Cloning Site (MCS) Compatibility:
[0055] When inserting a DNA fragment into a vector, it is necessary to consider the existing restriction sites in the multiple cloning site on the vector and select an enzyme that matches the existing restriction sites on the vector to ensure correct insertion and directional connection.
[0056] End complementarity after enzyme digestion:
[0057] If two or more fragments need to be connected, select an enzyme that can produce complementary ends, so that stable sticky end pairing can be formed during connection, improving the connection efficiency.
[0058] Distribution and functional regions of restriction sites:
[0059] Avoid restriction sites located in important functional regions (such as promoters, coding sequences or regulatory elements) to avoid affecting gene expression or protein function.
[0060] Enzyme availability and cost:
[0061] Consider the existing resources in the laboratory and choose restriction endonucleases that are already in the laboratory or easy to purchase at a reasonable price.
[0062] Smooth connection after enzyme digestion:
[0063] If possible, try to choose an enzyme that does not leave overhanging bases or additional sequences at the cleavage site to avoid these sequences affecting ligation efficiency or causing unnecessary trouble.
[0064] Use the process management module to manage order data and nucleic acid sequence synthesis to complete vector construction;
[0065] The output of vector construction is a vector containing the nanobody gene. After evaluating the yield, solubility and stability in the protein expression step, the production effect processing module is used to evaluate the quality of vector construction in combination with the results of protein expression, and feedback and optimization of the experimental conditions in the vector construction step are provided.
[0066] In one embodiment of the present invention, in the protein expression step, the experimental condition design module is used to select the required strains, culture medium, control the environmental temperature and humidity of the bacteria, the amount of induced IPTG, and the induction time; the temperature of bacterial culture has a significant effect on the expression and folding of the protein. The common culture temperature range is 37°C, but sometimes lowering the temperature (such as 18°C to 30°C) can increase solubility and reduce protein degradation. According to the characteristics of the target protein and the required post-translational modifications, a suitable host strain is selected. Escherichia coli (E. coli) is the most commonly used expression system, among which strains such as BL21 (DE3) and Rosetta are favored for their expression efficiency and protein folding ability.
[0067] Use the process management module to strictly control the process and management of the expression process to ensure the yield and reproducibility of the final protein;
[0068] The production effect processing module is used to evaluate the yield, solubility and stability. If the effect is not ideal, the experimental conditions in vector construction and protein expression are fed back and optimized at the same time.
[0069] In one embodiment of the present invention, in the nano antibody purification step, the experimental condition design module is used to select the type of liquid chromatography technology and the type of chromatographic column filler to remove impurities and separate the target protein; HPLC is a high-efficiency liquid chromatography technology that uses high-pressure gradient elution and high-sensitivity detectors, which are suitable for fine separation and purification. The HPLC system can be used with various types of chromatographic columns, such as C18 columns commonly used in RP-HPLC, while other types of columns are used for specific separation tasks. The type of chromatographic column filler selects affinity resin or reverse phase resin.
[0070] Use the process management module to manage nanoantibody samples, perform process control and management on each component used in the purification process, and ensure the quality and purity of the final protein;
[0071] The production effect processing module is used to evaluate the yield, concentration and purity of the purified nanoantibodies; if the effect is not ideal, feedback and optimization of the experimental conditions in the protein purification step are required.
[0072] In one embodiment of the present invention, when the experimental conditions do not meet the set conditions and management, the system immediately issues an alarm to remind the experimenter, notifies the experimenter to stop the current experimental activities, and conducts a comprehensive inspection and review of the experimental conditions, determines the possible causes, and takes appropriate measures to correct them.
[0073] In one embodiment of the present invention, each protein expression and purification needs to be monitored at the beginning and during the process, and compared using software.
[0074] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. An AI-assisted production management system for nano-antibody recombinant expression, characterized in that: include: The experimental condition design module trains the nanobody recombinant expression and purification model based on the relevant data in the existing nanobody recombinant expression database, recommends more optimized experimental conditions, and predicts the production effect that can be achieved by each combination of experimental conditions; Process management module, which sets the order between experimental steps or modules to achieve the management of multiple experiments; Production effect processing module, which is used for abnormal evaluation, comparison, early warning and feedback.
2. An application of an AI-assisted production management system for nano-antibody recombinant expression, characterized in that: The production management system is applied to vector construction, protein expression and protein purification to evaluate the nanobody production, solubility, stability, concentration and purity data, and establish a data analysis model to generate anomaly coefficients, which are compared with the pre-designed anomaly coefficient reference thresholds to complete the recombinant expression of nanobodies.
3. The use of an AI-assisted production management system for nano-antibody recombinant expression as claimed in claim 2, characterized in that: In the vector construction step, the experimental condition design module is used to select the vector, restriction enzyme sites and antibiotics; Use the process management module to manage order data and nucleic acid sequence synthesis to complete vector construction; The output of vector construction is a vector containing the nanobody gene. After evaluating the yield, solubility and stability in the protein expression step, the production effect processing module is used to evaluate the quality of vector construction in combination with the results of protein expression, and feedback and optimization of the experimental conditions in the vector construction step are provided.
4. The use of an AI-assisted production management system for nano-antibody recombinant expression as claimed in claim 3, characterized in that: In the protein expression step, the experimental condition design module is used to select the required strain, culture medium, control the environmental temperature and humidity of the strain, the amount of induced IPTG, and the induction time; Use the process management module to strictly control the process and management of the expression process to ensure the yield and reproducibility of the final protein; The production effect processing module is used to evaluate the yield, solubility and stability. If the effect is not ideal, the experimental conditions in vector construction and protein expression are fed back and optimized at the same time.
5. The use of an AI-assisted production management system for nanobody recombinant expression as claimed in claim 4, characterized in that: In the protein purification step, the experimental condition design module is used to select the type of liquid chromatography technology and column filler type to remove impurities and separate the target protein; Use the process management module to manage nano antibody protein samples, perform process control and management on each component used in the purification process, and ensure the quality and purity of the final protein; The production effect processing module is used to evaluate the yield, concentration and purity of the purified nanoantibody protein; if the effect is not ideal, feedback and optimization of the experimental conditions in the protein purification step are required.
6. The use of an AI-assisted production management system for nanobody recombinant expression as claimed in claim 5, characterized in that: When the yield, solubility and stability do not meet the standards in the protein expression step, one or more of the vector, restriction enzyme cleavage site and antibiotic are reselected. For the vector, according to the characteristics of the nanoantibody and the required post-translational modification, a suitable host cell such as Escherichia coli, yeast, insect cells or mammalian cells is selected; for the restriction enzyme cleavage site, the size of the DNA fragment generated after the selected enzyme cleavage is changed.
7. The use of an AI-assisted production management system for nanobody recombinant expression as claimed in claim 5, characterized in that: In the protein purification step, affinity chromatography or reverse phase chromatography is selected for liquid chromatography, and Ni-NTA resin, GST resin or C18 resin is selected as the chromatographic column filler.
8. The use of an AI-assisted production management system for nanobody recombinant expression as claimed in claim 5, characterized in that: When the experimental conditions do not meet the set conditions and management, the system immediately issues an alarm to remind the experimenter, notifies the experimenter to stop the current experimental activities, and conducts a comprehensive inspection and review of the experimental conditions, determines the possible causes, and takes appropriate measures to correct them.
9. The use of an AI-assisted production management system for nanobody recombinant expression as claimed in claim 8, characterized in that: Each protein expression and purification process needs to be monitored at the beginning and during the process and compared using software.
